New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
07:06 EDTIMGN
theflyonthewall.com: ImmunoGen option prices elevated into data
ImmunoGen closed at $8.58. ImmunoGen most advanced compound, trastuzumab-DM1 (breast cancer treatment) is in Phase three testing, and data is expected before year end. ImmunGen December 7.5 straddle is priced at $3.00, January 7.5 straddle is priced at $3.90. IMGN December and January option implied volatility of 145 is above its 26-week average of 78 according to Track Data, suggesting large price movement. :theflyonthewall.com



News For IMGN From The Last 14 Days
Check below for free stories on IMGN the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2010
16:08 EDTIMGN
theflyonthewall.com: ImmunoGen sees FY10 net loss $53M-$56M

Subscribe for More Information :theflyonthewall.com
16:08 EDTIMGN
theflyonthewall.com: ImmunoGen reports Q2 EPS (23c) vs. consensus of (21c)
Reports Q2 revenue $3.11M vs. consensus $4.33M. :theflyonthewall.com

January 27, 2010
07:00 EDTIMGN
theflyonthewall.com: ImmunoGen initiated with a Buy at Canaccord

Subscribe for More Information :theflyonthewall.com